The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 328:847-854 March 25, 1993 Number 12
NextNext

Association between High Levels of Expression of the TRK Gene and Favorable Outcome in Human Neuroblastoma
Akira Nakagawara, Miwako Arima-Nakagawara, Nancy J. Scavarda, Christopher G. Azar, Alan B. Cantor, and Garrett M. Brodeur

 Sign up for free e-toc
 

This Article
-Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background and Methods The nerve growth factor receptor is expressed in some neuroblastomas, in which its primary component is encoded by the TRK proto-oncogene. To determine the relation of the expression of TRK messenger RNA in neuroblastomas to other clinical and laboratory variables, we studied frozen tumor samples from 77 patients. In addition, we tested two primary neuroblastomas that expressed TRK for responsiveness to nerve growth factor.

Results TRK expression strongly correlated with favorable tumor stage (I, II, and IVS vs. III and IV), younger age (<1 year vs. >= 1 year), normal N-myc copy number, and low level of N-myc expression. N-myc amplification (indicated by a high copy number) correlated with advanced tumor stage, older age, an adrenal site of the primary tumor, low level of expression of TRK, and high level of expression of N-myc. Analysis of five-year cumulative-survival rates demonstrated an association of a very favorable outcome with a high level of TRK expression (86 percent vs. 14 percent) and with normal N-myc copy number (84 percent vs. 0 percent). Univariate analysis showed that these two variables were the most powerful predictors of outcome (chi-square = 51.30, P<0.001; and chi-square = 93.61, P<0.001, respectively). TRK expression still had significant prognostic value when the analysis was restricted to tumors without N-myc amplification. In primary cultures of neuroblastoma cells expressing TRK, exposure to nerve growth factor induced early gene expression and neurite outgrowth, but deprivation of nerve growth factor led to neuronal cell death.

Conclusions A high level of expression of the TRK proto-oncogene in a neuroblastoma is strongly predictive of a favorable outcome. A tumor with a functional nerve growth factor receptor may be dependent on the neurotrophin nerve growth factor for survival and may regress in its absence, allowing a new approach to the treatment of certain patients with neuroblastoma. .


Source Information

From the Department of Pediatrics, Washington University School of Medicine, St. Louis (A.N., M.A.-N., N.J.S., C.G.A., G.M.B.), the Pediatric Oncology Group Statistical Office, Gainesville, Fla. (A.B.C.), and the Pediatric Oncology Group, St. Louis (G.M.B., A.B.C.).

Address reprint requests to Dr. Brodeur at the Department of Pediatrics, Washington University School of Medicine, 1 Children's Place, St. Louis, MO 63110.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.